西达基奥仑赛(一种抗B细胞成熟抗原的嵌合抗原受体T细胞疗法)治疗复发/难治性多发性骨髓瘤:CARTITUDE-1研究2年随访
CARTITUDE-1是一项Ib/II期研究,评估西达基奥仑赛(cilta-cel)在重度经治复发/难治性多发性骨髓瘤患者中的安全性和疗效。中位随访27.7个月时,总缓解率97.9%,82.5%达严格完全缓解,27个月无进展生存率和总生存率分别为54.9%和70.4%,高危亚组缓解率亦高但生存较短,安全性可控。
要点
- 中位随访27.7个月,总缓解率97.9%,82.5%达严格完全缓解。
- 27个月无进展生存率54.9%,总生存率70.4%,中位值未达到。
- 高危细胞遗传学、ISS III期、高肿瘤负荷或浆细胞瘤患者缓解持续时间、无进展生存和/或总生存较短。
核心结论
- 中位随访约28个月时,接受西达基奥仑赛治疗的患者维持深度且持久的缓解,标准和高危亚组均可见。
- 随着随访时间延长,西达基奥仑赛的风险获益特征保持有利。
研究设计与样本
- CARTITUDE-1为Ib/II期研究,评估西达基奥仑赛在重度经治复发/难治性多发性骨髓瘤患者中的安全性和疗效。
- 入组患者为复发/难治性多发性骨髓瘤,既往接受≥3线治疗或对蛋白酶体抑制剂和免疫调节药物双重难治,且既往接受过蛋白酶体抑制剂、免疫调节药物和抗CD38治疗。
- 患者在淋巴细胞清除后5-7天接受单次西达基奥仑赛输注,缓解由独立审查委员会评估。
- 本次报告为末例患者入组后2年(中位随访约28个月)的更新结果,包括高危患者亚组分析。
主要发现
- 中位随访27.7个月(N=97),总缓解率为97.9%(95%CI,92.7至99.7)。
- 82.5%(95%CI,73.4至89.4)的患者达到严格完全缓解。
- 缓解持续时间中位值不可估计;中位无进展生存和总生存均未达到。
- 27个月无进展生存率为54.9%(95%CI,44.0至64.6),27个月总生存率为70.4%(95%CI,60.1至78.6)。
- 所有亚组总缓解率均高(95.1%-100%);高危细胞遗传学、国际分期系统III期、高肿瘤负荷或浆细胞瘤患者缓解持续时间、无进展生存和/或总生存较短。
临床怎么用
- 自上次报告以来,安全性特征可控,无新的西达基奥仑赛相关细胞因子释放综合征,新增1例帕金森综合征(西达基奥仑赛后第914天)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: CARTITUDE-1, a phase Ib/II study evaluating the safety and efficacy of ciltacabtagene autoleucel (cilta-cel) in heavily pretreated patients with relapsed/refractory multiple myeloma, yielded early, deep, and durable responses at 12 months. Here, we present updated results 2 years after last patient in (median follow-up [MFU] approximately 28 months), including analyses of high-risk patient subgroups. METHODS: Eligible patients had relapsed/refractory multiple myeloma, had received ≥ 3 prior lines of therapy or were double refractory to a proteasome inhibitor and immunomodulatory drug and had received prior proteasome inhibitor, immunomodulatory drug, and anti-CD38 therapy. Patients received a single cilta-cel infusion 5-7 days after lymphodepletion. Responses were assessed by an independent review committee. RESULTS: At a MFU of 27.7 months (N = 97), the overall response rate was 97.9% (95% CI, 92.7 to 99.7); 82.5% (95% CI, 73.4 to 89.4) of patients achieved a stringent complete response. Median duration of response was not estimable. Median progression-free survival (PFS) and overall survival (OS) were not reached; 27-month PFS and OS rates were 54.9% (95% CI, 44.0 to 64.6) and 70.4% (95% CI, 60.1 to 78.6), respectively. Overall response rates were high across all subgroups (95.1%-100%). Duration of response, PFS, and/or OS were shorter in patients with high-risk cytogenetics, International Staging System stage III, high tumor burden, or plasmacytomas. The safety profile was manageable with no new cilta-cel-related cytokine release syndrome and one new case of parkinsonism (day 914 after cilta-cel) since the last report. CONCLUSION: At approximately 28 months MFU, patients treated with cilta-cel maintained deep and durable responses, observed in both standard and high-risk subgroups. The risk/benefit profile of cilta-cel remained favorable with longer follow-up.
引用
- Martin T, Usmani SZ, Berdeja JG, et al. Ciltacabtagene Autoleucel, an Anti-B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up. J Clin Oncol. 2022. PMID: 35658469. doi:10.1200/JCO.22.00842
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。